Log in with your email address username.


[Correspondence] 10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS

ATLAS is an international trial of the main effects of prolonging adjuvant tamoxifen. It involves 15 000 women with early breast cancer, randomised in 1995–2005 at 402 centres in many countries. Its 2013 findings1 showed that in oestrogen receptor (ER)-positive disease, 5 years of tamoxifen is significantly less effective than 10 years in reducing 15-year breast cancer mortality, and its 20-year findings are to be reported in 2018.